Mesoblast (MESO) vs Novavax (NVAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Novavax (NVAX) has outperformed Mesoblast (MESO) over the past year, gaining 21.7% versus a loss of 22.9%. Over five years, MESO leads with a +22.7% price change compared with -93.1% for NVAX. Novavax is the larger company by market cap ($1.79 billion vs $1.74 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MESO | NVAX |
|---|---|---|
| Share price | $13.43 | $10.88 |
| Market cap | $1.74B | $1.79B |
| 1-day change | -3.70% | -3.07% |
| YTD return | -22.73% | +66.96% |
| 1-year return | -22.94% | +21.69% |
| 5-year return | +22.71% | -93.07% |
| Forward P/E | 29.51 | — |
| EPS (TTM) | $-0.44 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.50 | $13.39 |
| 52-week low | $13.05 | $6.20 |
| Distance from 52-week high | -37.56% | -18.78% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +175.61% | +28.74% |
| Average volume | 232.53K | 5.16M |
| Shares outstanding | 129.85M | 164.95M |
| Employees | 108 | 749 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVAX has outperformed MESO by 44.6 percentage points over the past year.
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
MESO vs NVAX FAQ
Which is bigger, Mesoblast or Novavax?
Novavax (NVAX) is larger, with a market capitalization of $1.79B compared with $1.74B for Mesoblast (MESO).
Which stock has performed better over the past year, MESO or NVAX?
NVAX returned +21.69% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Mesoblast and Novavax in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.